The study, which began before states started legalizing cannabis, published its results on the impact of a legal cannabis environment on cannabis use and alcohol use disorder.
A peer-reviewed, longitudinal study recently published in the journal Psychological Medicine suggested that people who live in states where cannabis was legal experienced lower rates of alcohol use disorder (AUD) compared to those who lived in states where cannabis was illegal (1). The study, funded by grants from the National Institutes of Health, involved 240 pairs of twins (one twin living in a state with legalized cannabis, and the other twin in a state where cannabis was illegal) and sought to quantify the impact of recreational cannabis on substance use, day-to-day functioning, and whether vulnerable people are more susceptible to potential negative effects than others (1).
The “Results” section of the paper stated (2): “In the co-twin control design accounting for earlier cannabis frequency and alcohol use disorder symptoms respectively, the twin living in a recreational state used cannabis on average more often, and had fewer AUD symptoms than their co-twin living in a non-recreational state. Cannabis legalization was associated with no other adverse outcome in the co-twin design, including cannabis use disorder. No risk factor significantly interacted with legalization status to predict any outcome.”
“Recreational legalization was associated with increased cannabis use and decreased AUD symptoms, but was not associated with other maladaptations” (2), the authors of the study concluded. “Moreover, vulnerabilities to cannabis use were not exacerbated by the legal cannabis environment.”
The authors did acknowledge that not all outcomes typically associated with cannabis use were evaluated and that a broadly characterized sample population was used (1). In its conclusion, the study suggested that further research could investigate causal links between cannabis consumption and outcomes (2). “Prevention and intervention efforts may be best implemented by continuing to target established risk factors rather than focusing on availability,” they also concluded (1).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.